<PAGE>

                       SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549

                                    FORM 10-Q

 /x/ QUARTERLY REPORT PURSUANT TO SECTION 13 or 15(d) OF THE
     SECURITIES EXCHANGE ACT OF 1934

For Quarter Ended December 31, 1999
                         OR

/ / TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
    SECURITIES EXCHANGE ACT OF 1934

For the transition period from _________________ to __________________

                    Commission File Number 0-6516

                   DATASCOPE CORP.
-----------------------------------------------------
(Exact name of registrant as specified in its charter)

Delaware                                                      13-2529596
------------------------------------------------------------------------------
(State of other jurisdiction of             (I.R.S. Employer
incorporation or organization)              Identification No.)

       14 Philips Parkway, Montvale, New Jersey  07645-9998
----------------------------------------------------------------
(Address of principal executive offices)        (Zip Code)

Registrant's telephone number, including area code  (201) 391-8100

------------------------------------------------------------------------------
Former name, former address and former fiscal year, if changed since last
report:

          Indicate by check mark whether the registrant

          (1)  has filed all reports required to be filed by Section 13 or 15
               (d) of the Securities Exchange Act of 1934 during the preceding
               12 months (or for such shorter period that the registrant was
               required to file such reports), and
          (2)  has been subject to such filing requirements for the past 90
               days.

                               YES  X    NO
                                   ---      ---

Number of Shares of Company's Common Stock outstanding as of January 31, 2000:
15,060,120.


<PAGE>

                        Datascope Corp. and Subsidiaries
                     Management's Discussion and Analysis of
                  Results of Operations and Financial Condition

Results of Operations

     The following is a comparison of the second quarter and first six months of
     fiscal 2000 with the second quarter and first six months of fiscal 1999.

     Net Sales
     ---------

         Net sales were $74.8 million in the second quarter and $138.3 million
         in the first six months of fiscal 2000 representing an increase of 12%
         and 13% compared to the second quarter and first six months of fiscal
         1999.

         Sales of the Cardiac Assist / Monitoring Products segment increased 7%
         to $56.3 million in the second quarter and 7% to $103.2 million in the
         first six months of fiscal 2000.

              Sales of cardiac assist products increased 8% to $29.3 million in
              the second quarter and 7% to $54.5 million in the first six months
              of fiscal 2000. The higher sales were attributable to continued
              excellent worldwide market acceptance of the Profile 8 Fr.
              intra-aortic balloon catheter and the System 98 balloon pump. Both
              of these products, introduced to the market last year, continue to
              contribute to the Company's substantial market share. During the
              second quarter, Profile 8 Fr. sales exceeded 50% of worldwide
              balloon catheter sales.

              Sales of patient monitoring products increased 7% to $27.1 million
              in the second quarter and 8% to $48.7 million in the first six
              months of fiscal 2000. The increased sales resulted primarily from
              higher shipments of the Passport portable monitor and the newer
              Accutorr(R) Plus blood pressure monitor. During the second
              quarter, the Company introduced Passport 2, a new generation of
              portable bedside monitors, to the international markets. Shipments
              began in late December and production is ramping up to satisfy
              backlog and a strong incoming order rate.

         Sales of the Collagen Products / Vascular Grafts segment increased 29%
         to $18.5 million in the second quarter and 33% to $35.1 million in the
         first six months of fiscal 2000.

              Sales of VasoSeal(R) arterial puncture sealing devices climbed 39%
              to a record $13.3 million in the second quarter and 42% to $25.3
              million in the first six months of fiscal 2000. VasoSeal's strong
              sales growth reflects continued market growth, higher average
              selling prices and greater productivity from the expanded

<PAGE>

              field sales organization. The VasoSeal product line consists of
              the VasoSeal VHD, the original VasoSeal, and VasoSeal ES which was
              introduced worldwide in the first quarter of fiscal 2000. In
              January 2000, VasoSeal VHD was cleared for reimbursement for
              certain procedures by the Ministry of Health in Japan. We expect
              that this clearance will provide a competitive advantage and
              stimulate sales growth in Japan over time.

         Sales of InterVascular, Inc. increased 7% to $4.9 million in the second
         quarter and 12% to $9.6 million in the first six months of fiscal 2000.
         The sales increase was attributable to continued strong demand for new
         products, particularly the InterGard(R) Silver, the world's first
         anti-microbial vascular graft which was launched in Europe during the
         fourth quarter last year. International sales, which account for a
         substantial portion of total sales, increased 22% in the second quarter
         and 19% in the first six months of fiscal 2000. Domestic sales declined
         sharply in the second quarter and first six months of fiscal 2000 as
         the Company's U.S. distributor reduced its inventory.

         The stronger U.S. dollar compared to major European currencies
         decreased total sales by approximately $1 million in the second quarter
         and $1.3 million in the first six months of fiscal 2000.

     Gross Profit (Net Sales Less Cost of Sales)
     -------------------------------------------

         The gross profit percentage was 61.5% for the second quarter and 61.7%
         for the first six months of fiscal 2000, compared to 61.5% and 61.4%
         for the corresponding periods last year. The gross profit percentage in
         the second quarter and first six months of fiscal 2000 benefitted from
         increased sales of higher margin products, which was offset by lower
         average selling prices for patient monitoring products.

     Research and Development (R&D)
     ------------------------------

         R&D expenses, as a percentage of sales, were 8.3% for the second
         quarter and 9.2% for the first six months of fiscal 2000, compared to
         11.1% and 12.5% for the corresponding periods last year.

         R&D expenses were $6.2 million in the second quarter and $12.8 million
         for the first six months of fiscal 2000 compared to $7.4 million and
         $15.3 million for the corresponding periods last year. The decrease was
         primarily due to cost savings from the restructuring program
         implemented in the second half of last year and reduced development
         expenses in the Patient Monitoring product line.

     Selling, General & Administrative Expenses (SG&A)
     -------------------------------------------------

         SG&A expenses, as a percentage of sales, were 40.1% in the second
         quarter and 40.9% in the first six months of fiscal 2000, compared to
         38.7% and 40.3% in the corresponding periods last year.

<PAGE>

         SG&A expenses increased $4.2 million or 16% in the second quarter and
         $7.3 million or 15% in the first six months of fiscal 2000 as a result
         of increased corporate expenses and higher selling expenses in the
         VasoSeal and Patient Monitoring product lines, resulting from the sales
         force expansions.

         The stronger U.S. dollar compared to major European currencies
         decreased SG&A expenses by approximately $600 thousand in the second
         quarter and $900 thousand in the first six months of fiscal 2000.

     Interest Income and Expense
     ---------------------------

         Interest income in the second quarter of $0.8 million was unchanged
         compared to the second quarter last year. Interest income was $1.7
         million for the first six months of fiscal 2000 compared to $1.8
         million last year, with the 7% decline attributable to a 4% reduction
         in the average investment portfolio from $67.6 million to $65.2 million
         and a decline in the average yield to 5.3% from 5.5% . The decline in
         the average investment portfolio of $2.4 million reflected cash
         utilization for (a) the stock repurchase program, (b) inventory to
         support new product introductions, and (c) capital expenditures related
         to the new Patient Monitoring facility in Mahwah, New Jersey.

     Income Taxes
     ------------

         The consolidated effective tax rate was 31.0% for the second quarter
         and first six months of fiscal 2000 and fiscal 1999.

     Net Earnings
     ------------

         Net earnings increased 25% to $7.4 million or $0.46 per diluted share
         in the second quarter of fiscal 2000 compared to $5.9 million, or
         $0.38 per diluted share. Net earnings for the first six months of
         fiscal 2000 were $12.2 million or $0.76 per diluted share compared to
         $8.6 million or $0.55 per diluted share for the first six months last
         year. The increase in earnings primarily reflects:
              o   sales growth in all product lines
              o   a more profitable product mix, and
              o   the cost savings from the restructuring program implemented in
                  the second half of fiscal 1999.

Liquidity and Capital Resources

     Working capital was $128.6 million at December 31, 1999 compared to $125.4
     million at June 30, 1999. The current ratio was unchanged at 4.0:1.

     In the first six months of fiscal 2000 cash provided by operations was
     $12.4 million, compared to a cash use of $4.9 million last year. The
     improvement is primarily attributable to higher net earnings, depreciation
     and amortization, and lower accounts

<PAGE>

     receivable, partially offset by increased inventories to support new
     product introductions. Net cash used in investing activities was $5.9
     million, primarily attributable to the purchase of $8.2 million of
     property, plant and equipment and a significant increase in the purchases
     of marketable securities, partially offset by maturities of marketable
     securities. Net cash used in financing activities was $8.1 million,
     attributable to the stock repurchase program completed in September 1999
     ($10.3 million), partially offset by cash received from exercise of stock
     options.

     On September 14, 1999 we announced a program to buy $30 million of our
     common stock. In September 1999, we completed our second stock repurchase
     program to buy $20 million of our common stock.

     On December 7, 1999, the Board of Directors inaugurated a quarterly cash
     dividend of $0.04 per share payable on January 14, 2000 to stockholders of
     record at December 18, 1999.

     We believe our financial resources are sufficient to meet our projected
     cash requirements.

     The moderate rate of current U.S. inflation has not significantly affected
     the Company.

Year 2000

     The Year 2000 issue is a term used to describe problems that could have
     occurred when computer systems were unable to accurately interpret dates
     after December 31, 1999. These problems result from the fact that many
     software programs use the two digits "00" to represent the Year 2000.

     Starting in fiscal 1998 we commenced a program to identify, remediate, test
     and develop contingency plans for the Year 2000 issue in our computer
     information systems, products, vendors, suppliers and customers.

     As of February 11, 2000, we had not experienced any Year 2000 problems
     regarding our computer information systems, products, vendors, suppliers or
     customers that caused disruptions in any of our business operations.

     The cost to modify the computer software programs used in our CIS was
     covered by existing service agreements with the software vendors. The
     assessments, testing and verification of our CIS products was performed by
     existing staff and no significant outside resources were required. Despite
     the use of internal resources for the Year 2000 Program, there was no
     significant deferral of other CIS projects. We do not anticipate that any
     remaining cost for the Year 2000 Program will be material to our financial
     condition or results of operations.

<PAGE>

Euro Conversion

     As part of the European Economic and Monetary Union (EMU), a single
     currency (Euro) will replace the national currencies of most of the
     European countries in which we conduct our business. The conversion rates
     between the Euro and the participating nations' currencies have been fixed
     irrevocably as of January 1, 1999. During a transition period from January
     1, 1999 to December 31, 2001 parties may settle transactions using either
     Euro or the participating country's national currency. The participating
     national currencies will be removed from circulation between January 1,
     2002 and June 30, 2002 and replaced by Euro notes and coinage. Full
     conversion of all affected country operations to the Euro currency is
     expected to be completed by the time national currencies are removed from
     circulation.

     We are currently involved in the phased conversion to the Euro and the
     effects on revenues, costs and various business strategies are being
     assessed. We are able to conduct business in both the Euro and national
     currencies on an as needed basis, as required by the European Union. The
     cost of software and business process conversion is not expected to be
     material to our financial condition or results of operations.

Information Concerning Forward Looking Statements

     This Management's Discussion and Analysis of Results of Operations and
     Financial Condition includes forward-looking statements that involve risks
     and uncertainties because of the possibility that: market conditions may
     change, particularly as the result of competitive activity in the cardiac
     assist, vascular sealing device and other markets served by us, because of
     our dependence on our suppliers for certain patient monitoring and collagen
     products, the possibility that we will not gain market acceptance in Japan
     for VasoSeal VHD because the clinical practice of physicians and hospitals
     may not change to allow for reimbursement under the guidelines set by the
     Ministry of Health and the risk that we may not gain a competitive
     advantage because competitors may obtain Ministry of Health reimbursement
     approval for their vascular sealing devices. Additional risks are our
     ability to successfully introduce and gain market acceptance for new
     products, continued demand for our products generally, the rapid and
     significant changes that characterize the medical device and life science
     research industries and the ability to continue to respond to such
     technological changes and because the timing of regulatory approvals is
     uncertain, as well as other risks detailed from time to time in documents
     filed by Datascope with the Securities and Exchange Commission.

Quantitative and Qualitative Disclosures About Market Risk

     Due to the global nature of our operations, we are subject to the exposures
     that arise from foreign exchange rate fluctuations. Our objective in
     managing our exposure to foreign currency fluctuations is to minimize net
     earnings volatility associated with foreign exchange rate changes. We enter
     into foreign currency forward exchange contracts to hedge a substantial
     portion of the foreign currency transactions which are primarily related to
     certain intercompany receivables denominated in foreign currencies. Our
     hedging activities do not subject us to exchange rate risk because gains
     and losses on

<PAGE>

     these contracts offset losses and gains on the assets, liabilities and
     transactions being hedged.

     We do not use derivative financial instruments for trading purposes. None
     of our foreign currency forward exchange contracts are designated as
     economic hedges of our net investment in foreign subsidiaries.

     As of December 31, 1999, we had $4.1 million of foreign exchange forward
     contracts outstanding, all of which were in European currencies. The
     foreign exchange forward contracts generally have maturities that do not
     exceed 12 months and require us to exchange foreign currencies for U.S.
     dollars at maturity, at rates agreed to when the contract is signed.


<PAGE>

                        Datascope Corp. and Subsidiaries
                           Consolidated Balance Sheets
                                 (In thousands)

<TABLE>
<CAPTION>
                                                                                                  Dec 31,                  June 30,
                                                                                                    1999                     1999
                                                                                                  -------                  --------
Assets                                                                                          (unaudited)                   (a)
<S>                                                                                             <C>                       <C>
Current Assets:
  Cash and cash equivalents                                                                      $   3,067                $   4,572
  Short-term investments                                                                            50,383                   45,539
  Accounts receivable less allowance for
    doubtful accounts of $1,318 and $1,192                                                          58,458                   64,289
  Inventories                                                                                       49,369                   42,747
  Prepaid expenses and other current assets                                                         10,232                    9,439
                                                                                                 ---------                ---------
      Total Current Assets                                                                         171,509                  166,586

Property, Plant and Equipment, net of accumulated
    depreciation of $57,254 and $53,353                                                             69,723                   63,321
Non-Current Marketable Securities                                                                   13,368                   20,496
Other Assets                                                                                        20,740                   19,091
                                                                                                 ---------                ---------
                                                                                                 $ 275,340                $ 269,494
                                                                                                 =========                =========
Liabilities and Stockholders' Equity
Current Liabilities:
  Accounts payable                                                                               $  11,029                $  10,565
  Accrued expenses                                                                                  16,113                   10,721
  Accrued compensation                                                                              10,916                   13,804
  Deferred revenue                                                                                   3,977                    4,380
  Taxes on income                                                                                      924                    1,695
                                                                                                 ---------                ---------
      Total Current Liabilities                                                                     42,959                   41,165

Other Liabilities                                                                                   14,121                   13,874
Stockholders' Equity
  Preferred stock, par value $1.00 per share:
    Authorized 5 million shares; Issued, none                                                         --                       --
  Common stock, par value $.01 per share:
    Authorized, 45 million shares; Issued and
    outstanding, 16,788 and 16,663 shares                                                              168                      167
  Additional paid-in capital                                                                        55,612                   52,570
  Treasury stock at cost, 1,758 and 1,416 shares                                                   (41,501)                 (31,079)
  Retained earnings                                                                                210,521                  198,921
  Accumulated other comprehensive income                                                            (6,540)                  (6,124)
                                                                                                 ---------                ---------
                                                                                                   218,260                  214,455
                                                                                                 ---------                ---------
                                                                                                 $ 275,340                $ 269,494
                                                                                                 =========                =========

</TABLE>

                (a) Derived from audited financial statements
                See notes to consolidated financial statements

<PAGE>

                        Datascope Corp. and Subsidiaries
                       Statements of Consolidated Earnings
                    (In thousands, except per share amounts)
                                   (Unaudited)

<TABLE>
<CAPTION>
                                                                     Six Months Ended                      Three Months Ended
                                                                       December 31,                           December 31,
                                                              ---------------------------------------------------------------------
                                                                1999                1998                1999                1998
                                                              ---------           ---------           ---------           ---------
<S>                                                           <C>                 <C>                 <C>                 <C>
Net Sales                                                     $ 138,300           $ 122,400           $  74,800           $  66,700
                                                              ---------           ---------           ---------           ---------
Costs and Expenses:
  Cost of sales                                                  52,907              47,246              28,783              25,652
  Research and development
    expenses                                                     12,780              15,263               6,193               7,429
  Selling, general and
    administrative expenses                                      56,593              49,307              29,987              25,798
                                                              ---------           ---------           ---------           ---------
                                                                122,280             111,816              64,963              58,879
                                                              ---------           ---------           ---------           ---------
Operating Earnings                                               16,020              10,584               9,837               7,821
Other (Income) Expense:
  Interest income                                                (1,722)             (1,869)               (855)               (797)
  Interest expense                                                   10                  20                   8                  14
  Other, net                                                         50                  17                   2                  73
                                                              ---------           ---------           ---------           ---------
                                                                 (1,662)             (1,832)               (845)               (710)
                                                              ---------           ---------           ---------           ---------
Earnings Before Taxes on Income                                  17,682              12,416              10,682               8,531
Taxes on Income                                                   5,481               3,849               3,311               2,645
                                                              ---------           ---------           ---------           ---------
Net Earnings                                                  $  12,201           $   8,567           $   7,371           $   5,886
                                                              =========           =========           =========           =========

Earnings Per Share, Basic                                     $    0.81           $    0.56           $    0.49           $    0.39
                                                              =========           =========           =========           =========
Weighted Average Number of
  Common and Common Equivalent
  Shares Outstanding, Basic                                      15,101              15,296              14,995              15,174
                                                              =========           =========           =========           =========

Earnings Per Share, Diluted                                   $    0.76           $    0.55           $    0.46           $    0.38
                                                              =========           =========           =========           =========
Weighted Average Number of
  Common and Common Equivalent
  Shares Outstanding, Diluted                                    16,053              15,688              16,002              15,550
                                                              =========           =========           =========           =========

</TABLE>

                 See notes to consolidated financial statements

<PAGE>

                        Datascope Corp. and Subsidiaries
                      Statements of Consolidated Cash Flows
                             (Dollars in thousands)
                                   (Unaudited)
<TABLE>
<CAPTION>
                                                                                                           Six Months Ended
                                                                                                               December 31,
                                                                                                   --------------------------------
                                                                                                     1999                    1998
                                                                                                   --------                --------
<S>                                                                                                <C>                     <C>
Operating Activities:
  Net cash provided by (used in) operating activities                                              $ 12,402                $ (4,859)
                                                                                                   --------                --------

Investing Activities:
  Capital expenditures                                                                               (8,173)                 (5,105)
  Purchases of marketable securities                                                                (40,253)                (13,624)
  Maturities of marketable securities                                                                42,536                  38,367
  Acquisition of Polyprobe, Inc. and Alpha Probe, Inc.                                                 --                      (450)
                                                                                                   --------                --------
  Net cash (used in) provided by investing activities                                                (5,890)                 19,188
                                                                                                   --------                --------

Financing Activities:
  Treasury shares acquired under repurchase programs                                                (10,347)                (11,531)
  Exercise of stock options and other                                                                 2,205                     138
                                                                                                   --------                --------
  Net cash used in financing activities                                                              (8,142)                (11,393)
                                                                                                   --------                --------

  Effect of exchange rates on cash                                                                      125                     100
                                                                                                   --------                --------

(Decrease) increase in cash and cash equivalents                                                     (1,505)                  3,036
Cash and cash equivalents, beginning of period                                                        4,572                   3,364
                                                                                                   --------                --------

Cash and cash equivalents, end of period                                                           $  3,067                $  6,400
                                                                                                   ========                ========

Supplemental Cash Flow Information
  Cash Paid during the period for:
  Income taxes                                                                                     $  5,426                $  1,331
                                                                                                   --------                --------

  Non-cash transactions:
   Net transfers of inventory to fixed assets
    for use as demonstration equipment                                                             $  4,312                $  4,183
                                                                                                   --------                --------

  Issuance of common stock for acquisition
    of Polyprobe, Inc. and Alpha Probe, Inc.                                                       $   --                  $  2,700
                                                                                                   --------                --------

</TABLE>

                 See notes to consolidated financial statements

<PAGE>

                        Datascope Corp. and Subsidiaries
                   Notes to Consolidated Financial Statements
                 (Unaudited, in thousands except per share data)

1.  Basis of Presentation

The consolidated financial statements include the accounts of Datascope Corp.
and its subsidiaries (the "Company" - which may be referred to as "our", "us" or
"we").

The consolidated balance sheet as of December 31, 1999, the statements of
consolidated earnings for the three and six month periods ended December 31,
1999 and 1998 and the statements of cash flows for the six month periods ended
December 31, 1999 and 1998 have been prepared by the Company, without audit. In
our opinion, all adjustments (which include only normal recurring adjustments)
have been made that are necessary to present fairly the financial position,
results of operations and cash flows for all periods presented.

Certain information and footnote disclosures normally included in financial
statements prepared in accordance with generally accepted accounting principles
have been condensed or omitted. We recommend that you read these condensed
consolidated financial statements in conjunction with the financial statements
and notes included in our Annual Report on Form 10-K for the fiscal year ended
June 30, 1999. The results of operations for the period ended December 31, 1999
are not necessarily indicative of a full year's operations.

We have reclassified certain prior year information to conform with the current
year presentation.

2.  Inventories

Inventories are stated at the lower of cost or market, with cost determined on a
first-in, first-out basis.

                                                -------   --------
                                                Dec 31,   June 30,
                                                   1999      1999
                                                -------   -------
              Materials                         $19,117   $15,788
              Work in Process                     6,782     6,229
              Finished Goods                     23,470    20,730
                                                -------   -------
                                                $49,369   $42,747
                                                =======   =======

3.  Stockholders' Equity

Changes in the components of stockholders' equity for the six months ended
December 31, 1999 were as follows:

             Net income                                               $12,201
             Foreign currency translation adjustments                    (416)
             Common stock and additional paid-in
               capital effects of stock option activity                 2,968
             Cash dividends on common stock                              (601)
             Purchases under stock repurchase plans                   (10,347)
                                                                  -----------
             Total increase in stockholders' equity                    $3,805
                                                                  ===========

<PAGE>

                        Datascope Corp. and Subsidiaries
                   Notes to Consolidated Financial Statements
                 (Unaudited, in thousands except per share data)

4.  Earnings Per Share

In accordance with Financial Accounting Standard No. 128, "Earnings Per Share",
we disclose both Basic and Diluted Earnings Per Share. The reconciliation of
Basic Earnings Per Share to Diluted Earnings Per Share is as follows:

<TABLE>
<CAPTION>
---------------------------------      --------------------------------------      -------------------------------------
For Three Months Ended                           December 31, 1999                       December 31, 1998
---------------------------------      --------------------------------------      -------------------------------------
                                           Net                    Per Share             Net                  Per Share
Basic EPS                               Earnings       Shares       Amount           Earnings     Shares       Amount
---------                              ------------  ------------  ----------       -----------  ----------  -----------
<S>                                        <C>          <C>           <C>               <C>         <C>         <C>
Earnings available to
   common shareholders                      $7,371        14,995       $0.49            $5,886      15,174        $0.39

Diluted EPS
-----------
Options issued to employees                     --         1,007       (0.03)               --         376        (0.01)
                                       ------------  ------------  ----------       -----------  ----------  -----------
Earnings available to
   common shareholders
   plus assumed conversions                 $7,371        16,002       $0.46            $5,886      15,550        $0.38
                                       ============  ============  ==========       ===========  ==========  ===========

<CAPTION>
---------------------------------      ---------------------------------------      ------------------------------------
For Six Months Ended                             December 31, 1999                        December 31, 1998
---------------------------------      ---------------------------------------      ------------------------------------
                                           Net                    Per Share             Net                  Per Share
Basic EPS                               Earnings       Shares       Amount           Earnings     Shares       Amount
---------                              ------------  ------------  ----------       -----------  ----------  -----------
<S>                                    <C>           <C>           <C>              <C>          <C>         <C>
Earnings available to
   common shareholders                     $12,201        15,101       $0.81            $8,567      15,296        $0.56

Diluted EPS
-----------
Options issued to employees                     --           952       (0.05)               --         392        (0.01)
                                       ------------  ------------  ----------       -----------  ----------  -----------

Earnings available to
   common shareholders
   plus assumed conversions                $12,201        16,053       $0.76            $8,567      15,688        $0.55
                                       ============  ============  ==========       ===========  ==========  ===========

</TABLE>

5.  Comprehensive Income

In accordance with Financial Accounting Standard No. 130, "Reporting
Comprehensive Income", we disclose comprehensive income and its components. For
the three and six month periods ended December 31, 1999 and 1998 our
comprehensive income was as follows:
<TABLE>
<CAPTION>
                                                        Six Months Ended              Three Months Ended
                                                     ------------------------       -----------------------
                                                       12/31/99     12/31/98          12/31/99    12/31/98
                                                     ------------  ----------        ----------  ----------
<S>                                                      <C>          <C>               <C>         <C>
           Net earnings                                  $12,201      $8,567            $7,371      $5,886
           Foreign currency translation
                   gain or (loss)                           (416)      1,380            (1,108)          3
                                                     ------------  ----------       -----------  ----------
           Total comprehensive income                    $11,785      $9,947            $6,263      $5,889
                                                     ============  ==========       ===========  ==========
</TABLE>

SFAS No. 130 has had no effect on our reported results of operations or
financial position.

<PAGE>

                        Datascope Corp. and Subsidiaries
                   Notes to Consolidated Financial Statements
                 (Unaudited, in thousands except per share data)

6.  Segment Information

Our business is the development, manufacture and sale of medical devices. We
have two reportable segments, Cardiac Assist / Monitoring Products and Collagen
Products / Vascular Grafts.

The Cardiac Assist / Monitoring Products segment includes electronic
intra-aortic balloon pumps and catheters that are used in the treatment of
vascular disease and electronic physiological monitors that provide for patient
safety and management of patient care.

The Collagen Products / Vascular Grafts segment includes extravascular
hemostasis devices which are used to seal arterial puncture wounds to stop
bleeding after cardiovascular catheterization procedures and a proprietary line
of knitted and woven vascular grafts and patches for reconstructive vascular and
cardiovascular surgery.

We have aggregated our product lines into two segments based on similar
manufacturing processes, distribution channels, regulatory environments and
customers. Management evaluates the revenue and profitability performance of
each of our product lines to make operating and strategic decisions. We have no
intersegment revenue. Net sales and operating margin are shown below.

<TABLE>
<CAPTION>
                                                           Cardiac       Collagen
                                                          Assist /      Products /        Corporate
                                                         Monitoring      Vascular            and
                                                          Products        Grafts            Other         Consolidated
                                                        --------------  --------------  ---------------- ----------------
Three months ended December 31, 1999
-----------------------------------------------------
<S>                                                     <C>              <C>             <C>              <C>
Net sales to external customers                               $56,343         $18,457                --          $74,800
                                                        -----------------------------------------------------------------
Operating margin                                               $7,717          $2,675             ($555)          $9,837
                                                        -----------------------------------------------------------------

Three months ended December 31, 1998
-----------------------------------------------------
Net sales to external customers                               $52,439         $14,261                --          $66,700
                                                        -----------------------------------------------------------------
Operating margin                                               $7,791            $869             ($839)          $7,821
                                                        -----------------------------------------------------------------

Six months ended December 31, 1999
-----------------------------------------------------
Net sales to external customers                              $103,161         $35,139                --         $138,300
                                                        -----------------------------------------------------------------
Operating margin                                              $10,867          $6,166           ($1,013)         $16,020
                                                        -----------------------------------------------------------------

Six months ended December 31, 1998
-----------------------------------------------------
Net sales to external customers                               $95,997         $26,403                --         $122,400
                                                        -----------------------------------------------------------------
Operating margin                                              $11,018          $1,138           ($1,572)         $10,584
                                                        -----------------------------------------------------------------

<CAPTION>
Reconciliation to consolidated earnings                         Six Months Ended                Three Months Ended
                                                        -----------------------------------------------------------------
    before income taxes :                                    12/31/99        12/31/98          12/31/99         12/31/98
-----------------------------------------------------   --------------  --------------  ---------------- ----------------
<S>                                                     <C>             <C>             <C>              <C>
Consolidated operating margin                                 $16,020         $10,584            $9,837           $7,821
Interest income, net                                            1,712           1,849               847              783
Other (expense) income                                            (50)            (17)               (2)             (73)
                                                        --------------  --------------  ---------------- ----------------
Consolidated earnings before taxes                            $17,682         $12,416           $10,682           $8,531
                                                        ==============  ==============  ================ ================

</TABLE>

<PAGE>

                        Datascope Corp. and Subsidiaries
                   Notes to Consolidated Financial Statements
                 (Unaudited, in thousands except per share data)

7.  Restructuring Program

Based upon a review by senior management of all company operations, management
approved a restructuring plan in fiscal year 1999 to reduce the company's cost
structure and streamline certain operations. We recorded pre-tax restructuring
charges totaling $3.43 million, or $0.14 per share, related to the following
cost reduction initiatives :

     o    Closure of InterVascular's Clearwater, Florida leased manufacturing
          facility in order to reduce costs and centralize operations in our
          expanded manufacturing facility in LaCiotat, France.

     o    Workforce reductions in certain administrative, R&D and manufacturing
          positions throughout the company.

     o    Writedown of certain Genisphere fixed assets based on the revised
          market entry strategy for our proprietary 3DNA technology in which we
          will focus our product development on improving the performance of
          newly-developing technologies for drug discovery used by the
          pharmaceutical and biotech industries.

A summary of the restructuring charges and remaining liability at December 31,
1999 is shown below.

<TABLE>
<CAPTION>
                                                            Clearwater                     Genisphere
                                                               Plant        Employee          Asset
                                                              Closure       Severance       Writedown         Total
                                                          --------------  --------------  -------------- ---------------
<S>                                                       <C>             <C>             <C>            <C>
Fiscal 1999 restructuring charges                                  $880          $1,674            $875          $3,429
Utilized through December 31, 1999                                  584           1,123             875           2,582
                                                          --------------  --------------  -------------- ---------------
Remaining liability at December 31, 1999                           $296            $551              --            $847
                                                          ==============  ==============  ============== ===============

</TABLE>

The remaining liability is for severance payments for employees who will be
leaving over the next nine months. No significant additional expenditures are
anticipated to complete the restructuring program.

<PAGE>

Part II:

     Item 6. Exhibits and Reports on Form 8-K

              a.  Exhibits

                  none

              b.  Reports on Form 8-K. No reports on Form 8-K have been filed
                  during the quarter for which this report is filed.


<PAGE>

                                                                       Form 10-Q

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this Report to be signed on its behalf by the
undersigned, thereunto duly authorized.

                                       DATASCOPE CORP.
                                       Registrant

                                       By: \s\ Lawrence Saper
                                           -----------------------------
                                            Chairman of the Board and
                                            Chief Executive Officer

                                       By: \s\ Leonard S. Goodman
                                           -----------------------------
                                            Vice President, CFO and Treasurer


Dated:  February 11, 2000